Skip to menu Skip to content Skip to footer

An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies (2018-2025)

Experts

Professor Maher Gandhi

Honorary Professor
Mater Research Institute-UQ
Faculty of Medicine
Maher Gandhi
Maher Gandhi

Associate Professor Colm Keane

Principal Research Fellow
Frazer Institute
Faculty of Medicine
Colm Keane